{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:46:20Z","timestamp":1763142380770,"version":"3.28.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,24]]},"DOI":"10.7759\/cureus.74364","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T03:15:52Z","timestamp":1732504552000},"source":"Crossref","is-referenced-by-count":1,"title":["Insulinoma: Unraveling the Mystery of a Stealthy Culprit"],"prefix":"10.7759","author":[{"given":"Eram A","family":"Mahaldar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kulsum","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed I","family":"Shahbuddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.05.047","article-title":"Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors","volume":"135","author":"Metz DC","year":"2008","unstructured":"Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology. 2008, 135:1469-92. 10.1053\/j.gastro.2008.05.047","journal-title":"Gastroenterology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad641","article-title":"Approach to the patient: insulinoma","volume":"109","author":"Hofland J","year":"2024","unstructured":"Hofland J, Refardt JC, Feelders RA, Christ E, de Herder WW. Approach to the patient: insulinoma. J Clin Endocrinol Metab. 2024, 109:1109-18. 10.1210\/clinem\/dgad641","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v19.i6.829","article-title":"Diagnosis and management of insulinoma","volume":"19","author":"Okabayashi T","year":"2013","unstructured":"Okabayashi T, Shima Y, Sumiyoshi T, et al.. Diagnosis and management of insulinoma. World J Gastroenterol. 2013, 19:829-37. 10.3748\/wjg.v19.i6.829","journal-title":"World J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-07-0109","article-title":"Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism","volume":"157","author":"Vezzosi D","year":"2007","unstructured":"Vezzosi D, Bennet A, Fauvel J, Caron P. Insulin, C-peptide and proinsulin for the biochemical diagnosis of hypoglycaemia related to endogenous hyperinsulinism. Eur J Endocrinol. 2007, 157:75-83. 10.1530\/EJE-07-0109","journal-title":"Eur J Endocrinol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1159\/000098010","article-title":"Well-differentiated pancreatic tumor\/carcinoma: insulinoma","volume":"84","author":"de Herder WW","year":"2006","unstructured":"de Herder WW, Niederle B, Scoazec JY, et al.. Well-differentiated pancreatic tumor\/carcinoma: insulinoma. Neuroendocrinology. 2006, 84:183-8. 10.1159\/000098010","journal-title":"Neuroendocrinology"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s0025-619662083-7","article-title":"Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study","volume":"66","author":"Service FJ","year":"1991","unstructured":"Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991, 66:711-9. 10.1016\/s0025-619662083-7","journal-title":"Mayo Clin Proc"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad114.1007","article-title":"SAT142 utilization of continuous glucose monitoring in diagnosis and management of insulinoma","volume":"7","author":"Phan V","year":"2023","unstructured":"Phan V, Kretschmer P, Pittas AG. SAT142 utilization of continuous glucose monitoring in diagnosis and management of insulinoma. J Endocr Soc. 2023, 7:114. 10.1210\/jendso\/bvad114.1007","journal-title":"J Endocr Soc"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.85.9.6807","article-title":"Forty-eight-hour fast: the diagnostic test for insulinoma","volume":"85","author":"Hirshberg B","year":"2000","unstructured":"Hirshberg B, Livi A, Bartlett DL, et al.. Forty-eight-hour fast: the diagnostic test for insulinoma. J Clin Endocrinol Metab. 2000, 85:3222-6. 10.1210\/jcem.85.9.6807","journal-title":"J Clin Endocrinol Metab"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1530\/EDM-20-0132","article-title":"Successful medical management of insulinoma with diazoxide for 27 years","volume":"2020","author":"Warren AM","year":"2020","unstructured":"Warren AM, Topliss DJ, Hamblin PS. Successful medical management of insulinoma with diazoxide for 27 years. Endocrinol Diabetes Metab Case Rep. 2020, 2020:32. 10.1530\/EDM-20-0132","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-1479","article-title":"Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients","volume":"92","author":"Kauhanen S","year":"2007","unstructured":"Kauhanen S, Sepp\u00e4nen M, Minn H, et al.. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or beta-cell hyperplasia in adult patients. J Clin Endocrinol Metab. 2007, 92:1237-44. 10.1210\/jc.2006-1479","journal-title":"J Clin Endocrinol Metab"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265894","article-title":"Peptide receptor radionuclide therapy is effective for clinical control of symptomatic metastatic insulinoma: a long-term retrospective analysis","volume":"65","author":"Friebe L","year":"2024","unstructured":"Friebe L, Freitag MT, Braun M, et al.. Peptide receptor radionuclide therapy is effective for clinical control of symptomatic metastatic insulinoma: a long-term retrospective analysis. J Nucl Med. 2024, 65:228-35. 10.2967\/jnumed.123.265894","journal-title":"J Nucl Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2147\/RRED.S86565","article-title":"Diagnosis and management of insulinoma: current best practice and ongoing developments","volume":"5","author":"Taye A","year":"2015","unstructured":"Taye A, Libutti S. Diagnosis and management of insulinoma: current best practice and ongoing developments. Res Rep Endocr Disord. 2015, 5:125-33. 10.2147\/RRED.S86565","journal-title":"Res Rep Endocr Disord"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ18-0353","article-title":"Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide","volume":"66","author":"Niitsu Y","year":"2019","unstructured":"Niitsu Y, Minami I, Izumiyama H, et al.. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J. 2019, 66:149-55. 10.1507\/endocrj.EJ18-0353","journal-title":"Endocr J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.01901","article-title":"Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies","volume":"152","author":"Vezzosi D","year":"2005","unstructured":"Vezzosi D, Bennet A, Rochaix P, et al.. Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies. Eur J Endocrinol. 2005, 152:757-67. 10.1530\/eje.1.01901","journal-title":"Eur J Endocrinol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-014-0294-4","article-title":"Targeting the mTOR signaling pathway in neuroendocrine tumors","volume":"15","author":"Chan J","year":"2014","unstructured":"Chan J, Kulke M. Targeting the mTOR signaling pathway in neuroendocrine tumors. Curr Treat Options Oncol. 2014, 15:365-79. 10.1007\/s11864-014-0294-4","journal-title":"Curr Treat Options Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.09.014","article-title":"mTOR inhibitors and diabetes","volume":"110","author":"Verg\u00e8s B","year":"2015","unstructured":"Verg\u00e8s B, Cariou B. mTOR inhibitors and diabetes. Diabetes Res Clin Pract. 2015, 110:101-8. 10.1016\/j.diabres.2015.09.014","journal-title":"Diabetes Res Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/319361-insulinoma-unraveling-the-mystery-of-a-stealthy-culprit","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T03:15:57Z","timestamp":1732504557000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/319361-insulinoma-unraveling-the-mystery-of-a-stealthy-culprit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,24]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.74364","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,24]]}}}